Patents by Inventor Qun Yin

Qun Yin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20070027074
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: May 12, 2004
    Publication date: February 1, 2007
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Peptides and compounds that bind to the IL-5 receptor
    Patent number: 7109299
    Abstract: Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX3VE X4 ARCPTCK, EGYVX3VE X4 ARCPTCK, EGYVX3VE X4 ARCPTCR, GYVX3VE X4 ARCPTCG, EGYVX3VE X4 ARCPTCG, GYVX3VE X4 ARCPTCR, and EGYVX3VE X4 AACPTCR, and methods of using the same, are described and claimed.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: September 19, 2006
    Assignee: Affymax, Inc.
    Inventors: Palani Balu, Qun Yin, Bruce England
  • Peptides that bind to the erythropoietin receptor
    Patent number: 7084245
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: August 1, 2006
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20060040858
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: October 27, 2005
    Publication date: February 23, 2006
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel peptides that bind to the erythropoietin receptor
    Publication number: 20050137329
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: May 12, 2004
    Publication date: June 23, 2005
    Applicant: Affymax, Inc.
    Inventors: Christopher Holmes, Qun Yin, Guy Lalonde, Peter Schatz, David Tumelty, Balu Palani, Genet Zemede
  • Novel poly(ethylene glycol) modified compounds and uses thereof
    Publication number: 20050107297
    Abstract: The present invention relates to a peptide-based compound comprising a peptide moiety and a poly(ethylene glycol) moiety wherein the poly(ethylene glycol) moiety (preferably linear) has a molecular weight of more than 20 KDaltons (preferably from 20 to 60 KDaltons). The peptide moiety may be monomeric, dimeric or oligomeric. Such peptide-based compounds may optional include a linker moiety and/or a spacer moiety.
    Type: Application
    Filed: May 12, 2004
    Publication date: May 19, 2005
    Inventors: Christopher Holmes, David Tumelty, Qun Yin
  • Labeled compounds that bind to a thrombopoietin receptor
    Patent number: 6506362
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: January 14, 2003
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Peptides and compounds that bind to a receptor
    Patent number: 6251864
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: June 26, 2001
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Peptides and compounds that bind to a receptor
    Patent number: 6121238
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: February 3, 1999
    Date of Patent: September 19, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Peptides and compounds that bind to a receptor
    Patent number: 5869451
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: February 9, 1999
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randoph B. DePrince, Surekha Podduturi, Qun Yin